Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adagene Inc ADR (ADAG)

Adagene Inc ADR (ADAG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,808
  • Shares Outstanding, K 44,157
  • Annual Sales, $ 18,110 K
  • Annual Income, $ -18,950 K
  • 60-Month Beta 0.65
  • Price/Sales 6.66
  • Price/Cash Flow N/A
  • Price/Book 1.71
Trade ADAG with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.47 +5.26%
on 06/18/24
3.18 -18.24%
on 06/27/24
-0.08 (-2.99%)
since 06/14/24
3-Month
2.01 +29.35%
on 05/10/24
3.18 -18.24%
on 06/27/24
-0.10 (-3.70%)
since 04/16/24
52-Week
1.10 +136.34%
on 08/31/23
4.38 -40.64%
on 01/26/24
+1.14 (+78.08%)
since 07/14/23

Most Recent Stories

More News
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 2.60 (-4.76%)
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

       - First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics -        - Additional data from...

ADAG : 2.60 (-4.76%)
Adagene to Participate in Investor Conferences in May and June

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 2.60 (-4.76%)
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings...

ADAG : 2.60 (-4.76%)
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and...

ADAG : 2.60 (-4.76%)
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting

- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging...

ADAG : 2.60 (-4.76%)
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

- Total potential transaction value of $2.5 billion plus royalties -    SAN DIEGO and SUZHOU, China, March 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc....

ADAG : 2.60 (-4.76%)
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 2.60 (-4.76%)
Adagene Announces Board and Management Appointments to Support Pipeline Growth

SAN DIEGO and SUZHOU, China, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and...

ADAG : 2.60 (-4.76%)
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

- Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision...

ADAG : 2.60 (-4.76%)

Business Summary

Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 2.92
2nd Resistance Point 2.85
1st Resistance Point 2.73
Last Price 2.60
1st Support Level 2.54
2nd Support Level 2.47
3rd Support Level 2.35

See More

52-Week High 4.38
Fibonacci 61.8% 3.13
Fibonacci 50% 2.74
Last Price 2.60
Fibonacci 38.2% 2.35
52-Week Low 1.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar